Review




Structured Review

Proteintech c3 targeting antibody
C3 Targeting Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c3 targeting antibody/product/Proteintech
Average 86 stars, based on 1 article reviews
c3 targeting antibody - by Bioz Stars, 2025-04
86/100 stars

Images



Similar Products

94
Hycult Biotech antibodies targeting c3
Antibodies Targeting C3, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies targeting c3/product/Hycult Biotech
Average 94 stars, based on 1 article reviews
antibodies targeting c3 - by Bioz Stars, 2025-04
94/100 stars
  Buy from Supplier

93
Novus Biologicals antibodies targeting c3b d
Antibodies Targeting C3b D, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies targeting c3b d/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
antibodies targeting c3b d - by Bioz Stars, 2025-04
93/100 stars
  Buy from Supplier

86
Danaher Inc antibodies targeting c3
Repeated lidocaine exposure promotes the transformation of astrocytes from the A2 phenotype to the A1 phenotype in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by <t>C3</t> in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), a neuroprotective marker (labeled by S100A10 in red) and the cell nucleus (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of S100A100/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (E and F) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), BDNF (red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of BDNF/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (G–I) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Sin lido: single lidocaine exposure; Rep lido: repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the sin lido group. Data were presented as the mean ± SD. See also <xref ref-type=Figure S2 . " width="250" height="auto" />
Antibodies Targeting C3, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies targeting c3/product/Danaher Inc
Average 86 stars, based on 1 article reviews
antibodies targeting c3 - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Proteintech c3 targeting antibody
Repeated lidocaine exposure promotes the transformation of astrocytes from the A2 phenotype to the A1 phenotype in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by <t>C3</t> in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), a neuroprotective marker (labeled by S100A10 in red) and the cell nucleus (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of S100A100/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (E and F) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), BDNF (red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of BDNF/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (G–I) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Sin lido: single lidocaine exposure; Rep lido: repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the sin lido group. Data were presented as the mean ± SD. See also <xref ref-type=Figure S2 . " width="250" height="auto" />
C3 Targeting Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c3 targeting antibody/product/Proteintech
Average 86 stars, based on 1 article reviews
c3 targeting antibody - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

86
Thermo Fisher c3 v5 targeting abs
Repeated lidocaine exposure promotes the transformation of astrocytes from the A2 phenotype to the A1 phenotype in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by <t>C3</t> in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), a neuroprotective marker (labeled by S100A10 in red) and the cell nucleus (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of S100A100/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (E and F) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), BDNF (red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of BDNF/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (G–I) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Sin lido: single lidocaine exposure; Rep lido: repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the sin lido group. Data were presented as the mean ± SD. See also <xref ref-type=Figure S2 . " width="250" height="auto" />
C3 V5 Targeting Abs, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c3 v5 targeting abs/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
c3 v5 targeting abs - by Bioz Stars, 2025-04
86/100 stars
  Buy from Supplier

Image Search Results


Repeated lidocaine exposure promotes the transformation of astrocytes from the A2 phenotype to the A1 phenotype in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by C3 in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), a neuroprotective marker (labeled by S100A10 in red) and the cell nucleus (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of S100A100/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (E and F) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), BDNF (red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of BDNF/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (G–I) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Sin lido: single lidocaine exposure; Rep lido: repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the sin lido group. Data were presented as the mean ± SD. See also <xref ref-type=Figure S2 . " width="100%" height="100%">

Journal: iScience

Article Title: Repeated lidocaine exposure induces synaptic and cognitive impairment in aged mice by activating microglia and neurotoxic A1 astrocytes

doi: 10.1016/j.isci.2025.112041

Figure Lengend Snippet: Repeated lidocaine exposure promotes the transformation of astrocytes from the A2 phenotype to the A1 phenotype in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by C3 in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), a neuroprotective marker (labeled by S100A10 in red) and the cell nucleus (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of S100A100/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (E and F) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), BDNF (red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of BDNF/GFAP-positive cells per field for each group ( n = 4, scale bar: 50 μm). (G–I) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Sin lido: single lidocaine exposure; Rep lido: repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the sin lido group. Data were presented as the mean ± SD. See also Figure S2 .

Article Snippet: After blocking with 5% fetal bovine serum, the sections were incubated overnight with primary antibodies targeting C3 (#ab200999, Abcam), S100A10 (#ab76472, Abcam), BDNF (#ab108319, Abcam), GFAP (GA5) (#3670, Cell Signaling Technology), and Iba-1 (#019-19741, WAKO, Osaka, Japan).

Techniques: Transformation Assay, Immunofluorescence, Staining, Labeling, Marker, Western Blot, Control

Microglial depletion by PLX5622 treatment attenuated A1 astrocyte activation and synaptic impairment induced by repeated lidocaine exposure in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of microglia (labeled by Iba-1 in green) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of microglia per field for each group ( n = 6, scale bar: 100 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by C3 in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 6, scale bar: 50 μm). (E–H) Representative western blot of proinflammatory cytokine IL-1α, TNF-α, and C1qA proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (I–K) Representative western blot of PSD95 and synaptophysin in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Lido: group that received repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the lido group. Data were presented as the mean ± SD.

Journal: iScience

Article Title: Repeated lidocaine exposure induces synaptic and cognitive impairment in aged mice by activating microglia and neurotoxic A1 astrocytes

doi: 10.1016/j.isci.2025.112041

Figure Lengend Snippet: Microglial depletion by PLX5622 treatment attenuated A1 astrocyte activation and synaptic impairment induced by repeated lidocaine exposure in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of microglia (labeled by Iba-1 in green) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of microglia per field for each group ( n = 6, scale bar: 100 μm). (C and D) Representative pictures of immunofluorescence staining of astrocytes (labeled by GFAP in green), neurotoxic markers (labeled by C3 in red) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of C3/GFAP-positive cells per field for each group ( n = 6, scale bar: 50 μm). (E–H) Representative western blot of proinflammatory cytokine IL-1α, TNF-α, and C1qA proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (I–K) Representative western blot of PSD95 and synaptophysin in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Con: control group; Lido: group that received repeated lidocaine exposure. ∗ p < 0.05 compared with the con group, # p < 0.05 compared with the lido group. Data were presented as the mean ± SD.

Article Snippet: After blocking with 5% fetal bovine serum, the sections were incubated overnight with primary antibodies targeting C3 (#ab200999, Abcam), S100A10 (#ab76472, Abcam), BDNF (#ab108319, Abcam), GFAP (GA5) (#3670, Cell Signaling Technology), and Iba-1 (#019-19741, WAKO, Osaka, Japan).

Techniques: Activation Assay, Immunofluorescence, Staining, Labeling, Western Blot, Control

DHMEQ treatment prevented microglial activation and A1 astrocyte polarization induced by repeated lidocaine exposure in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of microglia (labeled by Iba-1 in green) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of microglia per field for each group ( n = 6, scale bar: 100 μm). (C–E) Representative western blot of p-IκBα, IκBα, p-NF-κB p65, and NF-κB p65 proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (F–I) Representative western blot of proinflammatory cytokine IL-1α, TNF-α and C1qA proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (J–L) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Veh: vehicle group; lido: group that received repeated lidocaine exposure. ∗ p < 0.05 compared with the veh group, # p < 0.05 compared with lido group. Data were presented as the mean ± SD. See also <xref ref-type=Figure S3 . " width="100%" height="100%">

Journal: iScience

Article Title: Repeated lidocaine exposure induces synaptic and cognitive impairment in aged mice by activating microglia and neurotoxic A1 astrocytes

doi: 10.1016/j.isci.2025.112041

Figure Lengend Snippet: DHMEQ treatment prevented microglial activation and A1 astrocyte polarization induced by repeated lidocaine exposure in the hippocampus of aged mice (A and B) Representative pictures of immunofluorescence staining of microglia (labeled by Iba-1 in green) and cell nuclei (labeled by DAPI in blue) in the hippocampal CA1 region. The statistical chart presents the number of microglia per field for each group ( n = 6, scale bar: 100 μm). (C–E) Representative western blot of p-IκBα, IκBα, p-NF-κB p65, and NF-κB p65 proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (F–I) Representative western blot of proinflammatory cytokine IL-1α, TNF-α and C1qA proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). (J–L) Representative western blot of C3 and BDNF proteins in the hippocampus. Densitometric analyses of the immunoblots were performed, and the results are expressed as percentages relative to the control group ( n = 4). Veh: vehicle group; lido: group that received repeated lidocaine exposure. ∗ p < 0.05 compared with the veh group, # p < 0.05 compared with lido group. Data were presented as the mean ± SD. See also Figure S3 .

Article Snippet: After blocking with 5% fetal bovine serum, the sections were incubated overnight with primary antibodies targeting C3 (#ab200999, Abcam), S100A10 (#ab76472, Abcam), BDNF (#ab108319, Abcam), GFAP (GA5) (#3670, Cell Signaling Technology), and Iba-1 (#019-19741, WAKO, Osaka, Japan).

Techniques: Activation Assay, Immunofluorescence, Staining, Labeling, Western Blot, Control

Journal: iScience

Article Title: Repeated lidocaine exposure induces synaptic and cognitive impairment in aged mice by activating microglia and neurotoxic A1 astrocytes

doi: 10.1016/j.isci.2025.112041

Figure Lengend Snippet:

Article Snippet: After blocking with 5% fetal bovine serum, the sections were incubated overnight with primary antibodies targeting C3 (#ab200999, Abcam), S100A10 (#ab76472, Abcam), BDNF (#ab108319, Abcam), GFAP (GA5) (#3670, Cell Signaling Technology), and Iba-1 (#019-19741, WAKO, Osaka, Japan).

Techniques: Recombinant, Extraction